Table 2. Baseline characteristics of the demographic reporting adverse effects of tumor necrosis factor (TNF) inhibitors.

Drug	Total	Sex			Age (years)
		Female	Male	Unknown sex	<18	18-24	25-64	≥65	Unknown age
Infliximab	245,865	111,476	60,117	74,272	14,140	8,496	84,406	21,170	117,653
Adalimumab	658,932	422,397	199,322	37,213	12,814	17,453	257,969	82,617	288,079
Golimumab	94,119	65,440	18,448	10,231	462	1,092	42,417	14,453	35,695
Certolizumab	118,411	89,610	20,184	8,617	681	1,765	46,638	9,740	59,587
Etanercept	431,935	309,121	98,414	24,400	9,820	5,463	216,427	86,805	113,420
Total	1,549,262	998,044	396,485	154,733	37,917	34,269	647,857	214,785	614,434